nodes	percent_of_prediction	percent_of_DWPC	metapath
Sibutramine—obesity—type 2 diabetes mellitus	0.579	1	CtDrD
Sibutramine—CYP3A4—type 2 diabetes mellitus	0.133	1	CbGaD
Sibutramine—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0211	0.152	CbGbCtD
Sibutramine—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0188	0.136	CbGbCtD
Sibutramine—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0172	0.124	CbGbCtD
Sibutramine—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.015	0.109	CbGbCtD
Sibutramine—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0136	0.0982	CbGbCtD
Sibutramine—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0103	0.0744	CbGbCtD
Sibutramine—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00986	0.0713	CbGbCtD
Sibutramine—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00986	0.0713	CbGbCtD
Sibutramine—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00933	0.0675	CbGbCtD
Sibutramine—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00695	0.0503	CbGbCtD
Sibutramine—CYP3A4—Losartan—type 2 diabetes mellitus	0.00635	0.046	CbGbCtD
Sibutramine—SLC6A2—sympathetic nervous system—type 2 diabetes mellitus	0.0008	0.379	CbGeAlD
Sibutramine—SLC6A2—autonomic nervous system—type 2 diabetes mellitus	0.000538	0.255	CbGeAlD
Sibutramine—SLC6A3—nerve—type 2 diabetes mellitus	0.000375	0.178	CbGeAlD
Sibutramine—SLC6A2—nerve—type 2 diabetes mellitus	0.000302	0.143	CbGeAlD
Sibutramine—SLC6A4—Circadian rythm related genes—F7—type 2 diabetes mellitus	7.07e-05	0.00319	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC5A2—type 2 diabetes mellitus	7.05e-05	0.00318	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—CASP3—type 2 diabetes mellitus	6.97e-05	0.00314	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—ABCC8—type 2 diabetes mellitus	6.92e-05	0.00312	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—HK1—type 2 diabetes mellitus	6.76e-05	0.00305	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—SLC2A1—type 2 diabetes mellitus	6.68e-05	0.00302	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—SREBF1—type 2 diabetes mellitus	6.65e-05	0.003	CbGpPWpGaD
Sibutramine—SLC6A2—Monoamine Transport—TNF—type 2 diabetes mellitus	6.56e-05	0.00296	CbGpPWpGaD
Sibutramine—SLC6A3—Dopaminergic Neurogenesis—TGFB1—type 2 diabetes mellitus	6.55e-05	0.00296	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—GCKR—type 2 diabetes mellitus	6.53e-05	0.00295	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—GJA1—type 2 diabetes mellitus	6.51e-05	0.00294	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—TGFBR2—type 2 diabetes mellitus	6.48e-05	0.00292	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—AR—type 2 diabetes mellitus	6.46e-05	0.00292	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—SLC2A4—type 2 diabetes mellitus	6.4e-05	0.00289	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—HMOX1—type 2 diabetes mellitus	6.39e-05	0.00288	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—GHRL—type 2 diabetes mellitus	6.3e-05	0.00285	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—ADIPOQ—type 2 diabetes mellitus	6.11e-05	0.00276	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—GNB3—type 2 diabetes mellitus	6.09e-05	0.00275	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—PPARGC1A—type 2 diabetes mellitus	6.09e-05	0.00275	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GAD2—type 2 diabetes mellitus	6.05e-05	0.00273	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—AVP—type 2 diabetes mellitus	6e-05	0.00271	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—HK1—type 2 diabetes mellitus	5.99e-05	0.0027	CbGpPWpGaD
Sibutramine—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—type 2 diabetes mellitus	5.97e-05	0.00269	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—GSTM1—type 2 diabetes mellitus	5.95e-05	0.00269	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—SLC2A1—type 2 diabetes mellitus	5.92e-05	0.00267	CbGpPWpGaD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—type 2 diabetes mellitus	5.88e-05	0.00265	CbGpPWpGaD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—type 2 diabetes mellitus	5.81e-05	0.00262	CbGpPWpGaD
Sibutramine—SLC6A3—Monoamine Transport—TNF—type 2 diabetes mellitus	5.81e-05	0.00262	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—GCKR—type 2 diabetes mellitus	5.79e-05	0.00261	CbGpPWpGaD
Sibutramine—CYP3A4—kidney—type 2 diabetes mellitus	5.77e-05	0.0274	CbGeAlD
Sibutramine—SLC6A4—NRF2 pathway—AGER—type 2 diabetes mellitus	5.74e-05	0.00259	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—SLC2A4—type 2 diabetes mellitus	5.67e-05	0.00256	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—TGFBR2—type 2 diabetes mellitus	5.57e-05	0.00251	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—HMOX1—type 2 diabetes mellitus	5.49e-05	0.00248	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—KCNJ11—type 2 diabetes mellitus	5.47e-05	0.00247	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC2A2—type 2 diabetes mellitus	5.44e-05	0.00245	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC5A4—type 2 diabetes mellitus	5.33e-05	0.00241	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—NR3C1—type 2 diabetes mellitus	5.22e-05	0.00236	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—GCK—type 2 diabetes mellitus	5.19e-05	0.00234	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—TRPC1—type 2 diabetes mellitus	5.15e-05	0.00233	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—G6PC—type 2 diabetes mellitus	5.15e-05	0.00233	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—GSTM1—type 2 diabetes mellitus	5.12e-05	0.00231	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—SNAP25—type 2 diabetes mellitus	5.09e-05	0.0023	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC9A1—type 2 diabetes mellitus	5.06e-05	0.00229	CbGpPWpGaD
Sibutramine—CYP3A4—Constitutive Androstane Receptor Pathway—PPARGC1A—type 2 diabetes mellitus	5.04e-05	0.00228	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—PPARGC1A—type 2 diabetes mellitus	4.97e-05	0.00224	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—AGER—type 2 diabetes mellitus	4.94e-05	0.00223	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—TGFBR2—type 2 diabetes mellitus	4.93e-05	0.00223	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—AVP—type 2 diabetes mellitus	4.9e-05	0.00221	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—HMOX1—type 2 diabetes mellitus	4.87e-05	0.0022	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC2A2—type 2 diabetes mellitus	4.82e-05	0.00217	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—SIRT1—type 2 diabetes mellitus	4.81e-05	0.00217	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—HIF1A—type 2 diabetes mellitus	4.76e-05	0.00215	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC5A4—type 2 diabetes mellitus	4.72e-05	0.00213	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—PLN—type 2 diabetes mellitus	4.71e-05	0.00213	CbGpPWpGaD
Sibutramine—CYP3A4—Tryptophan metabolism—CYP2E1—type 2 diabetes mellitus	4.62e-05	0.00208	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—GCK—type 2 diabetes mellitus	4.6e-05	0.00208	CbGpPWpGaD
Sibutramine—CYP3A4—Tryptophan metabolism—CYP1A2—type 2 diabetes mellitus	4.56e-05	0.00206	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—G6PC—type 2 diabetes mellitus	4.56e-05	0.00206	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—TRPC1—type 2 diabetes mellitus	4.56e-05	0.00206	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—GSTM1—type 2 diabetes mellitus	4.53e-05	0.00205	CbGpPWpGaD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—type 2 diabetes mellitus	4.52e-05	0.00204	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC9A1—type 2 diabetes mellitus	4.49e-05	0.00203	CbGpPWpGaD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—type 2 diabetes mellitus	4.46e-05	0.00201	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—AGER—type 2 diabetes mellitus	4.37e-05	0.00197	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC2A1—type 2 diabetes mellitus	4.21e-05	0.0019	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC30A8—type 2 diabetes mellitus	4.2e-05	0.0019	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ABCC8—type 2 diabetes mellitus	4.2e-05	0.0019	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—PLN—type 2 diabetes mellitus	4.17e-05	0.00188	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—FAS—type 2 diabetes mellitus	4.13e-05	0.00187	CbGpPWpGaD
Sibutramine—Infection—Metformin—type 2 diabetes mellitus	4.07e-05	0.000324	CcSEcCtD
Sibutramine—Insomnia—Valsartan—type 2 diabetes mellitus	4.07e-05	0.000324	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	4.05e-05	0.000323	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—COX2—type 2 diabetes mellitus	4.04e-05	0.00182	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC5A2—type 2 diabetes mellitus	4.04e-05	0.00182	CbGpPWpGaD
Sibutramine—Paraesthesia—Valsartan—type 2 diabetes mellitus	4.04e-05	0.000322	CcSEcCtD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC2A4—type 2 diabetes mellitus	4.04e-05	0.00182	CbGpPWpGaD
Sibutramine—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	4.03e-05	0.000322	CcSEcCtD
Sibutramine—Chest pain—Irbesartan—type 2 diabetes mellitus	4.03e-05	0.000321	CcSEcCtD
Sibutramine—Myalgia—Irbesartan—type 2 diabetes mellitus	4.03e-05	0.000321	CcSEcCtD
Sibutramine—Arthralgia—Irbesartan—type 2 diabetes mellitus	4.03e-05	0.000321	CcSEcCtD
Sibutramine—Shock—Metformin—type 2 diabetes mellitus	4.03e-05	0.000321	CcSEcCtD
Sibutramine—Insomnia—Orlistat—type 2 diabetes mellitus	4.02e-05	0.00032	CcSEcCtD
Sibutramine—Malaise—Losartan—type 2 diabetes mellitus	4.02e-05	0.00032	CcSEcCtD
Sibutramine—Anxiety—Irbesartan—type 2 diabetes mellitus	4.02e-05	0.00032	CcSEcCtD
Sibutramine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	4.02e-05	0.00032	CcSEcCtD
Sibutramine—Thrombocytopenia—Metformin—type 2 diabetes mellitus	4.01e-05	0.00032	CcSEcCtD
Sibutramine—Dyspnoea—Valsartan—type 2 diabetes mellitus	4.01e-05	0.00032	CcSEcCtD
Sibutramine—Vertigo—Losartan—type 2 diabetes mellitus	4.01e-05	0.000319	CcSEcCtD
Sibutramine—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	4e-05	0.000319	CcSEcCtD
Sibutramine—Somnolence—Valsartan—type 2 diabetes mellitus	4e-05	0.000319	CcSEcCtD
Sibutramine—Syncope—Losartan—type 2 diabetes mellitus	4e-05	0.000319	CcSEcCtD
Sibutramine—SLC6A4—Circadian rythm related genes—PPARA—type 2 diabetes mellitus	4e-05	0.0018	CbGpPWpGaD
Sibutramine—Paraesthesia—Orlistat—type 2 diabetes mellitus	3.99e-05	0.000318	CcSEcCtD
Sibutramine—Leukopenia—Losartan—type 2 diabetes mellitus	3.99e-05	0.000318	CcSEcCtD
Sibutramine—Discomfort—Irbesartan—type 2 diabetes mellitus	3.98e-05	0.000318	CcSEcCtD
Sibutramine—Skin disorder—Metformin—type 2 diabetes mellitus	3.98e-05	0.000317	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—NCOA6—type 2 diabetes mellitus	3.97e-05	0.00179	CbGpPWpGaD
Sibutramine—Immune system disorder—Ramipril—type 2 diabetes mellitus	3.97e-05	0.000316	CcSEcCtD
Sibutramine—CYP3A4—Biological oxidations—MAT1A—type 2 diabetes mellitus	3.96e-05	0.00179	CbGpPWpGaD
Sibutramine—Hyperhidrosis—Metformin—type 2 diabetes mellitus	3.96e-05	0.000316	CcSEcCtD
Sibutramine—Dyspepsia—Valsartan—type 2 diabetes mellitus	3.96e-05	0.000316	CcSEcCtD
Sibutramine—Dizziness—Bromocriptine—type 2 diabetes mellitus	3.94e-05	0.000314	CcSEcCtD
Sibutramine—Dry mouth—Irbesartan—type 2 diabetes mellitus	3.94e-05	0.000314	CcSEcCtD
Sibutramine—Palpitations—Losartan—type 2 diabetes mellitus	3.94e-05	0.000314	CcSEcCtD
Sibutramine—Nausea—Glimepiride—type 2 diabetes mellitus	3.93e-05	0.000313	CcSEcCtD
Sibutramine—Arrhythmia—Ramipril—type 2 diabetes mellitus	3.92e-05	0.000313	CcSEcCtD
Sibutramine—Loss of consciousness—Losartan—type 2 diabetes mellitus	3.92e-05	0.000312	CcSEcCtD
Sibutramine—Nausea—Sitagliptin—type 2 diabetes mellitus	3.92e-05	0.000312	CcSEcCtD
Sibutramine—Dyspepsia—Orlistat—type 2 diabetes mellitus	3.91e-05	0.000312	CcSEcCtD
Sibutramine—Asthenia—Glyburide—type 2 diabetes mellitus	3.91e-05	0.000312	CcSEcCtD
Sibutramine—Decreased appetite—Valsartan—type 2 diabetes mellitus	3.91e-05	0.000312	CcSEcCtD
Sibutramine—Anorexia—Metformin—type 2 diabetes mellitus	3.9e-05	0.000311	CcSEcCtD
Sibutramine—SLC6A3—Neuronal System—SNAP25—type 2 diabetes mellitus	3.9e-05	0.00176	CbGpPWpGaD
Sibutramine—Cough—Losartan—type 2 diabetes mellitus	3.89e-05	0.00031	CcSEcCtD
Sibutramine—Urticaria—Gliclazide—type 2 diabetes mellitus	3.89e-05	0.00031	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	3.88e-05	0.00031	CcSEcCtD
Sibutramine—Alopecia—Ramipril—type 2 diabetes mellitus	3.88e-05	0.000309	CcSEcCtD
Sibutramine—Body temperature increased—Gliclazide—type 2 diabetes mellitus	3.87e-05	0.000309	CcSEcCtD
Sibutramine—Abdominal pain—Gliclazide—type 2 diabetes mellitus	3.87e-05	0.000309	CcSEcCtD
Sibutramine—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	3.87e-05	0.000308	CcSEcCtD
Sibutramine—Oedema—Irbesartan—type 2 diabetes mellitus	3.87e-05	0.000308	CcSEcCtD
Sibutramine—Decreased appetite—Orlistat—type 2 diabetes mellitus	3.86e-05	0.000308	CcSEcCtD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—type 2 diabetes mellitus	3.86e-05	0.00174	CbGpPWpGaD
Sibutramine—Pruritus—Glyburide—type 2 diabetes mellitus	3.86e-05	0.000308	CcSEcCtD
Sibutramine—Constipation—Valsartan—type 2 diabetes mellitus	3.85e-05	0.000307	CcSEcCtD
Sibutramine—Infection—Irbesartan—type 2 diabetes mellitus	3.84e-05	0.000306	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	3.84e-05	0.000306	CcSEcCtD
Sibutramine—Hypotension—Metformin—type 2 diabetes mellitus	3.83e-05	0.000305	CcSEcCtD
Sibutramine—Malnutrition—Ramipril—type 2 diabetes mellitus	3.82e-05	0.000305	CcSEcCtD
Sibutramine—Shock—Irbesartan—type 2 diabetes mellitus	3.8e-05	0.000303	CcSEcCtD
Sibutramine—Pain—Orlistat—type 2 diabetes mellitus	3.8e-05	0.000303	CcSEcCtD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—GNB3—type 2 diabetes mellitus	3.8e-05	0.00172	CbGpPWpGaD
Sibutramine—Myalgia—Losartan—type 2 diabetes mellitus	3.8e-05	0.000303	CcSEcCtD
Sibutramine—Chest pain—Losartan—type 2 diabetes mellitus	3.8e-05	0.000303	CcSEcCtD
Sibutramine—Arthralgia—Losartan—type 2 diabetes mellitus	3.8e-05	0.000303	CcSEcCtD
Sibutramine—SLC6A4—Circadian rythm related genes—LEP—type 2 diabetes mellitus	3.79e-05	0.00171	CbGpPWpGaD
Sibutramine—Vomiting—Bromocriptine—type 2 diabetes mellitus	3.79e-05	0.000302	CcSEcCtD
Sibutramine—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	3.79e-05	0.000302	CcSEcCtD
Sibutramine—Anxiety—Losartan—type 2 diabetes mellitus	3.78e-05	0.000301	CcSEcCtD
Sibutramine—Tachycardia—Irbesartan—type 2 diabetes mellitus	3.77e-05	0.000301	CcSEcCtD
Sibutramine—Rash—Bromocriptine—type 2 diabetes mellitus	3.76e-05	0.0003	CcSEcCtD
Sibutramine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	3.76e-05	0.0003	CcSEcCtD
Sibutramine—Skin disorder—Irbesartan—type 2 diabetes mellitus	3.76e-05	0.000299	CcSEcCtD
Sibutramine—Tension—Ramipril—type 2 diabetes mellitus	3.75e-05	0.000299	CcSEcCtD
Sibutramine—Discomfort—Losartan—type 2 diabetes mellitus	3.75e-05	0.000299	CcSEcCtD
Sibutramine—Dysgeusia—Ramipril—type 2 diabetes mellitus	3.74e-05	0.000298	CcSEcCtD
Sibutramine—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	3.74e-05	0.000298	CcSEcCtD
Sibutramine—Headache—Bromocriptine—type 2 diabetes mellitus	3.74e-05	0.000298	CcSEcCtD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—type 2 diabetes mellitus	3.73e-05	0.00169	CbGpPWpGaD
Sibutramine—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	3.73e-05	0.000297	CcSEcCtD
Sibutramine—Diarrhoea—Glyburide—type 2 diabetes mellitus	3.73e-05	0.000297	CcSEcCtD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC2A1—type 2 diabetes mellitus	3.73e-05	0.00168	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC30A8—type 2 diabetes mellitus	3.72e-05	0.00168	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ABCC8—type 2 diabetes mellitus	3.72e-05	0.00168	CbGpPWpGaD
Sibutramine—Nervousness—Ramipril—type 2 diabetes mellitus	3.71e-05	0.000296	CcSEcCtD
Sibutramine—Dry mouth—Losartan—type 2 diabetes mellitus	3.71e-05	0.000296	CcSEcCtD
Sibutramine—CYP3A4—Tryptophan metabolism—CAT—type 2 diabetes mellitus	3.7e-05	0.00167	CbGpPWpGaD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—type 2 diabetes mellitus	3.69e-05	0.00167	CbGpPWpGaD
Sibutramine—Anorexia—Irbesartan—type 2 diabetes mellitus	3.69e-05	0.000294	CcSEcCtD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—type 2 diabetes mellitus	3.68e-05	0.00166	CbGpPWpGaD
Sibutramine—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	3.68e-05	0.000293	CcSEcCtD
Sibutramine—Paraesthesia—Metformin—type 2 diabetes mellitus	3.68e-05	0.000293	CcSEcCtD
Sibutramine—Muscle spasms—Ramipril—type 2 diabetes mellitus	3.68e-05	0.000293	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ATP2A3—type 2 diabetes mellitus	3.67e-05	0.00166	CbGpPWpGaD
Sibutramine—Confusional state—Losartan—type 2 diabetes mellitus	3.67e-05	0.000292	CcSEcCtD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—type 2 diabetes mellitus	3.67e-05	0.00165	CbGpPWpGaD
Sibutramine—Feeling abnormal—Orlistat—type 2 diabetes mellitus	3.66e-05	0.000292	CcSEcCtD
Sibutramine—Dyspnoea—Metformin—type 2 diabetes mellitus	3.65e-05	0.000291	CcSEcCtD
Sibutramine—CYP3A4—liver—type 2 diabetes mellitus	3.65e-05	0.0173	CbGeAlD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—type 2 diabetes mellitus	3.64e-05	0.00164	CbGpPWpGaD
Sibutramine—Somnolence—Metformin—type 2 diabetes mellitus	3.64e-05	0.00029	CcSEcCtD
Sibutramine—Oedema—Losartan—type 2 diabetes mellitus	3.64e-05	0.00029	CcSEcCtD
Sibutramine—Anaphylactic shock—Losartan—type 2 diabetes mellitus	3.64e-05	0.00029	CcSEcCtD
Sibutramine—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	3.63e-05	0.00029	CcSEcCtD
Sibutramine—Infection—Losartan—type 2 diabetes mellitus	3.61e-05	0.000288	CcSEcCtD
Sibutramine—Hypotension—Irbesartan—type 2 diabetes mellitus	3.61e-05	0.000288	CcSEcCtD
Sibutramine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	3.61e-05	0.000288	CcSEcCtD
Sibutramine—Dyspepsia—Metformin—type 2 diabetes mellitus	3.61e-05	0.000287	CcSEcCtD
Sibutramine—Tremor—Ramipril—type 2 diabetes mellitus	3.58e-05	0.000285	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—COX2—type 2 diabetes mellitus	3.58e-05	0.00162	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC5A2—type 2 diabetes mellitus	3.58e-05	0.00162	CbGpPWpGaD
Sibutramine—Shock—Losartan—type 2 diabetes mellitus	3.58e-05	0.000285	CcSEcCtD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC2A4—type 2 diabetes mellitus	3.58e-05	0.00161	CbGpPWpGaD
Sibutramine—Urticaria—Valsartan—type 2 diabetes mellitus	3.57e-05	0.000285	CcSEcCtD
Sibutramine—Thrombocytopenia—Losartan—type 2 diabetes mellitus	3.56e-05	0.000284	CcSEcCtD
Sibutramine—Decreased appetite—Metformin—type 2 diabetes mellitus	3.56e-05	0.000284	CcSEcCtD
Sibutramine—Abdominal pain—Valsartan—type 2 diabetes mellitus	3.56e-05	0.000283	CcSEcCtD
Sibutramine—Tachycardia—Losartan—type 2 diabetes mellitus	3.55e-05	0.000283	CcSEcCtD
Sibutramine—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	3.55e-05	0.000283	CcSEcCtD
Sibutramine—Nausea—Bromocriptine—type 2 diabetes mellitus	3.54e-05	0.000282	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	3.54e-05	0.000282	CcSEcCtD
Sibutramine—SLC6A4—Circadian rythm related genes—NOS2—type 2 diabetes mellitus	3.53e-05	0.0016	CbGpPWpGaD
Sibutramine—Urticaria—Orlistat—type 2 diabetes mellitus	3.53e-05	0.000281	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	3.52e-05	0.000281	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—NCOA6—type 2 diabetes mellitus	3.52e-05	0.00159	CbGpPWpGaD
Sibutramine—Hyperhidrosis—Losartan—type 2 diabetes mellitus	3.52e-05	0.00028	CcSEcCtD
Sibutramine—Abdominal pain—Orlistat—type 2 diabetes mellitus	3.51e-05	0.00028	CcSEcCtD
Sibutramine—Body temperature increased—Orlistat—type 2 diabetes mellitus	3.51e-05	0.00028	CcSEcCtD
Sibutramine—Asthenia—Gliclazide—type 2 diabetes mellitus	3.51e-05	0.00028	CcSEcCtD
Sibutramine—Agitation—Ramipril—type 2 diabetes mellitus	3.51e-05	0.00028	CcSEcCtD
Sibutramine—Constipation—Metformin—type 2 diabetes mellitus	3.5e-05	0.000279	CcSEcCtD
Sibutramine—Angioedema—Ramipril—type 2 diabetes mellitus	3.49e-05	0.000278	CcSEcCtD
Sibutramine—Paraesthesia—Irbesartan—type 2 diabetes mellitus	3.47e-05	0.000277	CcSEcCtD
Sibutramine—Anorexia—Losartan—type 2 diabetes mellitus	3.47e-05	0.000276	CcSEcCtD
Sibutramine—Vomiting—Glyburide—type 2 diabetes mellitus	3.47e-05	0.000276	CcSEcCtD
Sibutramine—Pruritus—Gliclazide—type 2 diabetes mellitus	3.46e-05	0.000276	CcSEcCtD
Sibutramine—Malaise—Ramipril—type 2 diabetes mellitus	3.45e-05	0.000275	CcSEcCtD
Sibutramine—Dyspnoea—Irbesartan—type 2 diabetes mellitus	3.45e-05	0.000275	CcSEcCtD
Sibutramine—Rash—Glyburide—type 2 diabetes mellitus	3.44e-05	0.000274	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—HK1—type 2 diabetes mellitus	3.44e-05	0.00155	CbGpPWpGaD
Sibutramine—Somnolence—Irbesartan—type 2 diabetes mellitus	3.44e-05	0.000274	CcSEcCtD
Sibutramine—Dermatitis—Glyburide—type 2 diabetes mellitus	3.43e-05	0.000274	CcSEcCtD
Sibutramine—Vertigo—Ramipril—type 2 diabetes mellitus	3.43e-05	0.000274	CcSEcCtD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—AVP—type 2 diabetes mellitus	3.43e-05	0.00155	CbGpPWpGaD
Sibutramine—Syncope—Ramipril—type 2 diabetes mellitus	3.43e-05	0.000273	CcSEcCtD
Sibutramine—Leukopenia—Ramipril—type 2 diabetes mellitus	3.42e-05	0.000273	CcSEcCtD
Sibutramine—Headache—Glyburide—type 2 diabetes mellitus	3.42e-05	0.000272	CcSEcCtD
Sibutramine—Dyspepsia—Irbesartan—type 2 diabetes mellitus	3.4e-05	0.000271	CcSEcCtD
Sibutramine—Hypotension—Losartan—type 2 diabetes mellitus	3.4e-05	0.000271	CcSEcCtD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—ADCY5—type 2 diabetes mellitus	3.39e-05	0.00153	CbGpPWpGaD
Sibutramine—Palpitations—Ramipril—type 2 diabetes mellitus	3.38e-05	0.000269	CcSEcCtD
Sibutramine—Feeling abnormal—Metformin—type 2 diabetes mellitus	3.38e-05	0.000269	CcSEcCtD
Sibutramine—Decreased appetite—Irbesartan—type 2 diabetes mellitus	3.36e-05	0.000268	CcSEcCtD
Sibutramine—Loss of consciousness—Ramipril—type 2 diabetes mellitus	3.36e-05	0.000268	CcSEcCtD
Sibutramine—Diarrhoea—Gliclazide—type 2 diabetes mellitus	3.35e-05	0.000267	CcSEcCtD
Sibutramine—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	3.35e-05	0.000267	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	3.34e-05	0.000266	CcSEcCtD
Sibutramine—Cough—Ramipril—type 2 diabetes mellitus	3.34e-05	0.000266	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—GCKR—type 2 diabetes mellitus	3.32e-05	0.0015	CbGpPWpGaD
Sibutramine—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	3.31e-05	0.000264	CcSEcCtD
Sibutramine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	3.31e-05	0.000264	CcSEcCtD
Sibutramine—Convulsion—Ramipril—type 2 diabetes mellitus	3.31e-05	0.000264	CcSEcCtD
Sibutramine—Pain—Irbesartan—type 2 diabetes mellitus	3.31e-05	0.000264	CcSEcCtD
Sibutramine—Constipation—Irbesartan—type 2 diabetes mellitus	3.31e-05	0.000264	CcSEcCtD
Sibutramine—SLC6A4—Circadian rythm related genes—PPARG—type 2 diabetes mellitus	3.3e-05	0.00149	CbGpPWpGaD
Sibutramine—Insomnia—Losartan—type 2 diabetes mellitus	3.29e-05	0.000262	CcSEcCtD
Sibutramine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	3.28e-05	0.000261	CcSEcCtD
Sibutramine—Paraesthesia—Losartan—type 2 diabetes mellitus	3.27e-05	0.00026	CcSEcCtD
Sibutramine—Urticaria—Metformin—type 2 diabetes mellitus	3.25e-05	0.000259	CcSEcCtD
Sibutramine—Myalgia—Ramipril—type 2 diabetes mellitus	3.25e-05	0.000259	CcSEcCtD
Sibutramine—Arthralgia—Ramipril—type 2 diabetes mellitus	3.25e-05	0.000259	CcSEcCtD
Sibutramine—Chest pain—Ramipril—type 2 diabetes mellitus	3.25e-05	0.000259	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ATP2A3—type 2 diabetes mellitus	3.25e-05	0.00147	CbGpPWpGaD
Sibutramine—Dyspnoea—Losartan—type 2 diabetes mellitus	3.24e-05	0.000259	CcSEcCtD
Sibutramine—Anxiety—Ramipril—type 2 diabetes mellitus	3.24e-05	0.000258	CcSEcCtD
Sibutramine—Nausea—Glyburide—type 2 diabetes mellitus	3.24e-05	0.000258	CcSEcCtD
Sibutramine—Abdominal pain—Metformin—type 2 diabetes mellitus	3.24e-05	0.000258	CcSEcCtD
Sibutramine—Dizziness—Gliclazide—type 2 diabetes mellitus	3.24e-05	0.000258	CcSEcCtD
Sibutramine—Somnolence—Losartan—type 2 diabetes mellitus	3.23e-05	0.000258	CcSEcCtD
Sibutramine—Asthenia—Valsartan—type 2 diabetes mellitus	3.23e-05	0.000257	CcSEcCtD
Sibutramine—Discomfort—Ramipril—type 2 diabetes mellitus	3.22e-05	0.000256	CcSEcCtD
Sibutramine—Dyspepsia—Losartan—type 2 diabetes mellitus	3.2e-05	0.000255	CcSEcCtD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—type 2 diabetes mellitus	3.19e-05	0.00144	CbGpPWpGaD
Sibutramine—Asthenia—Orlistat—type 2 diabetes mellitus	3.19e-05	0.000254	CcSEcCtD
Sibutramine—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	3.19e-05	0.000254	CcSEcCtD
Sibutramine—Pruritus—Valsartan—type 2 diabetes mellitus	3.18e-05	0.000254	CcSEcCtD
Sibutramine—Dry mouth—Ramipril—type 2 diabetes mellitus	3.18e-05	0.000254	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ABCC2—type 2 diabetes mellitus	3.18e-05	0.00144	CbGpPWpGaD
Sibutramine—Decreased appetite—Losartan—type 2 diabetes mellitus	3.16e-05	0.000252	CcSEcCtD
Sibutramine—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	3.16e-05	0.000252	CcSEcCtD
Sibutramine—Confusional state—Ramipril—type 2 diabetes mellitus	3.15e-05	0.000251	CcSEcCtD
Sibutramine—Pruritus—Orlistat—type 2 diabetes mellitus	3.14e-05	0.000251	CcSEcCtD
Sibutramine—Oedema—Ramipril—type 2 diabetes mellitus	3.12e-05	0.000249	CcSEcCtD
Sibutramine—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	3.12e-05	0.000249	CcSEcCtD
Sibutramine—Vomiting—Gliclazide—type 2 diabetes mellitus	3.11e-05	0.000248	CcSEcCtD
Sibutramine—Pain—Losartan—type 2 diabetes mellitus	3.11e-05	0.000248	CcSEcCtD
Sibutramine—Constipation—Losartan—type 2 diabetes mellitus	3.11e-05	0.000248	CcSEcCtD
Sibutramine—Rash—Gliclazide—type 2 diabetes mellitus	3.09e-05	0.000246	CcSEcCtD
Sibutramine—Dermatitis—Gliclazide—type 2 diabetes mellitus	3.08e-05	0.000246	CcSEcCtD
Sibutramine—Diarrhoea—Valsartan—type 2 diabetes mellitus	3.08e-05	0.000245	CcSEcCtD
Sibutramine—Urticaria—Irbesartan—type 2 diabetes mellitus	3.07e-05	0.000245	CcSEcCtD
Sibutramine—Shock—Ramipril—type 2 diabetes mellitus	3.07e-05	0.000245	CcSEcCtD
Sibutramine—Headache—Gliclazide—type 2 diabetes mellitus	3.07e-05	0.000244	CcSEcCtD
Sibutramine—Abdominal pain—Irbesartan—type 2 diabetes mellitus	3.06e-05	0.000244	CcSEcCtD
Sibutramine—Body temperature increased—Irbesartan—type 2 diabetes mellitus	3.06e-05	0.000244	CcSEcCtD
Sibutramine—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	3.05e-05	0.000243	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—HK1—type 2 diabetes mellitus	3.04e-05	0.00137	CbGpPWpGaD
Sibutramine—Tachycardia—Ramipril—type 2 diabetes mellitus	3.04e-05	0.000243	CcSEcCtD
Sibutramine—Diarrhoea—Orlistat—type 2 diabetes mellitus	3.04e-05	0.000242	CcSEcCtD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—AVP—type 2 diabetes mellitus	3.04e-05	0.00137	CbGpPWpGaD
Sibutramine—Skin disorder—Ramipril—type 2 diabetes mellitus	3.03e-05	0.000242	CcSEcCtD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—type 2 diabetes mellitus	3.03e-05	0.00137	CbGpPWpGaD
Sibutramine—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	3.02e-05	0.00024	CcSEcCtD
Sibutramine—Feeling abnormal—Losartan—type 2 diabetes mellitus	3e-05	0.000239	CcSEcCtD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—type 2 diabetes mellitus	2.99e-05	0.00135	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—SERPINE1—type 2 diabetes mellitus	2.98e-05	0.00134	CbGpPWpGaD
Sibutramine—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	2.98e-05	0.000237	CcSEcCtD
Sibutramine—Dizziness—Valsartan—type 2 diabetes mellitus	2.97e-05	0.000237	CcSEcCtD
Sibutramine—Anorexia—Ramipril—type 2 diabetes mellitus	2.97e-05	0.000237	CcSEcCtD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—CASP3—type 2 diabetes mellitus	2.95e-05	0.00133	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—GCKR—type 2 diabetes mellitus	2.94e-05	0.00133	CbGpPWpGaD
Sibutramine—Dizziness—Orlistat—type 2 diabetes mellitus	2.94e-05	0.000234	CcSEcCtD
Sibutramine—Asthenia—Metformin—type 2 diabetes mellitus	2.94e-05	0.000234	CcSEcCtD
Sibutramine—Hypotension—Ramipril—type 2 diabetes mellitus	2.92e-05	0.000232	CcSEcCtD
Sibutramine—SLC6A3—Neuronal System—GNB3—type 2 diabetes mellitus	2.91e-05	0.00131	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—CALM1—type 2 diabetes mellitus	2.91e-05	0.00131	CbGpPWpGaD
Sibutramine—Nausea—Gliclazide—type 2 diabetes mellitus	2.91e-05	0.000232	CcSEcCtD
Sibutramine—Pruritus—Metformin—type 2 diabetes mellitus	2.9e-05	0.000231	CcSEcCtD
Sibutramine—Urticaria—Losartan—type 2 diabetes mellitus	2.89e-05	0.00023	CcSEcCtD
Sibutramine—Body temperature increased—Losartan—type 2 diabetes mellitus	2.88e-05	0.000229	CcSEcCtD
Sibutramine—Abdominal pain—Losartan—type 2 diabetes mellitus	2.88e-05	0.000229	CcSEcCtD
Sibutramine—Vomiting—Valsartan—type 2 diabetes mellitus	2.86e-05	0.000228	CcSEcCtD
Sibutramine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	2.85e-05	0.000227	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	2.84e-05	0.000227	CcSEcCtD
Sibutramine—Rash—Valsartan—type 2 diabetes mellitus	2.84e-05	0.000226	CcSEcCtD
Sibutramine—Dermatitis—Valsartan—type 2 diabetes mellitus	2.83e-05	0.000226	CcSEcCtD
Sibutramine—Vomiting—Orlistat—type 2 diabetes mellitus	2.83e-05	0.000225	CcSEcCtD
Sibutramine—Insomnia—Ramipril—type 2 diabetes mellitus	2.82e-05	0.000225	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ABCC2—type 2 diabetes mellitus	2.82e-05	0.00127	CbGpPWpGaD
Sibutramine—Headache—Valsartan—type 2 diabetes mellitus	2.82e-05	0.000225	CcSEcCtD
Sibutramine—Diarrhoea—Metformin—type 2 diabetes mellitus	2.8e-05	0.000223	CcSEcCtD
Sibutramine—Rash—Orlistat—type 2 diabetes mellitus	2.8e-05	0.000223	CcSEcCtD
Sibutramine—Paraesthesia—Ramipril—type 2 diabetes mellitus	2.8e-05	0.000223	CcSEcCtD
Sibutramine—Dermatitis—Orlistat—type 2 diabetes mellitus	2.8e-05	0.000223	CcSEcCtD
Sibutramine—Headache—Orlistat—type 2 diabetes mellitus	2.78e-05	0.000222	CcSEcCtD
Sibutramine—Dyspnoea—Ramipril—type 2 diabetes mellitus	2.78e-05	0.000222	CcSEcCtD
Sibutramine—Asthenia—Irbesartan—type 2 diabetes mellitus	2.77e-05	0.000221	CcSEcCtD
Sibutramine—Somnolence—Ramipril—type 2 diabetes mellitus	2.77e-05	0.000221	CcSEcCtD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—NFKB1—type 2 diabetes mellitus	2.76e-05	0.00125	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC2A2—type 2 diabetes mellitus	2.76e-05	0.00125	CbGpPWpGaD
Sibutramine—Dyspepsia—Ramipril—type 2 diabetes mellitus	2.75e-05	0.000219	CcSEcCtD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—PRKCB—type 2 diabetes mellitus	2.74e-05	0.00123	CbGpPWpGaD
Sibutramine—Pruritus—Irbesartan—type 2 diabetes mellitus	2.74e-05	0.000218	CcSEcCtD
Sibutramine—Decreased appetite—Ramipril—type 2 diabetes mellitus	2.71e-05	0.000216	CcSEcCtD
Sibutramine—Dizziness—Metformin—type 2 diabetes mellitus	2.71e-05	0.000216	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	2.69e-05	0.000215	CcSEcCtD
Sibutramine—Hypersensitivity—Losartan—type 2 diabetes mellitus	2.68e-05	0.000214	CcSEcCtD
Sibutramine—Nausea—Valsartan—type 2 diabetes mellitus	2.67e-05	0.000213	CcSEcCtD
Sibutramine—Constipation—Ramipril—type 2 diabetes mellitus	2.67e-05	0.000213	CcSEcCtD
Sibutramine—Diarrhoea—Irbesartan—type 2 diabetes mellitus	2.65e-05	0.000211	CcSEcCtD
Sibutramine—Nausea—Orlistat—type 2 diabetes mellitus	2.64e-05	0.00021	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—GCK—type 2 diabetes mellitus	2.64e-05	0.00119	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ATP2A2—type 2 diabetes mellitus	2.64e-05	0.00119	CbGpPWpGaD
Sibutramine—Asthenia—Losartan—type 2 diabetes mellitus	2.61e-05	0.000208	CcSEcCtD
Sibutramine—Vomiting—Metformin—type 2 diabetes mellitus	2.6e-05	0.000208	CcSEcCtD
Sibutramine—SLC6A3—Neuronal System—ADCY5—type 2 diabetes mellitus	2.6e-05	0.00117	CbGpPWpGaD
Sibutramine—Rash—Metformin—type 2 diabetes mellitus	2.58e-05	0.000206	CcSEcCtD
Sibutramine—Dermatitis—Metformin—type 2 diabetes mellitus	2.58e-05	0.000206	CcSEcCtD
Sibutramine—Pruritus—Losartan—type 2 diabetes mellitus	2.57e-05	0.000205	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC9A1—type 2 diabetes mellitus	2.57e-05	0.00116	CbGpPWpGaD
Sibutramine—Feeling abnormal—Ramipril—type 2 diabetes mellitus	2.57e-05	0.000205	CcSEcCtD
Sibutramine—Headache—Metformin—type 2 diabetes mellitus	2.57e-05	0.000205	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—TRPC6—type 2 diabetes mellitus	2.56e-05	0.00116	CbGpPWpGaD
Sibutramine—Dizziness—Irbesartan—type 2 diabetes mellitus	2.56e-05	0.000204	CcSEcCtD
Sibutramine—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	2.55e-05	0.000203	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—CETP—type 2 diabetes mellitus	2.54e-05	0.00115	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—type 2 diabetes mellitus	2.51e-05	0.00113	CbGpPWpGaD
Sibutramine—Diarrhoea—Losartan—type 2 diabetes mellitus	2.49e-05	0.000198	CcSEcCtD
Sibutramine—Urticaria—Ramipril—type 2 diabetes mellitus	2.48e-05	0.000198	CcSEcCtD
Sibutramine—Body temperature increased—Ramipril—type 2 diabetes mellitus	2.47e-05	0.000197	CcSEcCtD
Sibutramine—Abdominal pain—Ramipril—type 2 diabetes mellitus	2.47e-05	0.000197	CcSEcCtD
Sibutramine—Vomiting—Irbesartan—type 2 diabetes mellitus	2.46e-05	0.000196	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC2A2—type 2 diabetes mellitus	2.45e-05	0.0011	CbGpPWpGaD
Sibutramine—Rash—Irbesartan—type 2 diabetes mellitus	2.44e-05	0.000194	CcSEcCtD
Sibutramine—Dermatitis—Irbesartan—type 2 diabetes mellitus	2.44e-05	0.000194	CcSEcCtD
Sibutramine—Nausea—Metformin—type 2 diabetes mellitus	2.43e-05	0.000194	CcSEcCtD
Sibutramine—SLC6A4—NRF2 pathway—TGFB1—type 2 diabetes mellitus	2.43e-05	0.0011	CbGpPWpGaD
Sibutramine—Headache—Irbesartan—type 2 diabetes mellitus	2.42e-05	0.000193	CcSEcCtD
Sibutramine—Dizziness—Losartan—type 2 diabetes mellitus	2.41e-05	0.000192	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—GCK—type 2 diabetes mellitus	2.34e-05	0.00105	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ATP2A2—type 2 diabetes mellitus	2.34e-05	0.00105	CbGpPWpGaD
Sibutramine—Vomiting—Losartan—type 2 diabetes mellitus	2.31e-05	0.000184	CcSEcCtD
Sibutramine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	2.3e-05	0.000183	CcSEcCtD
Sibutramine—Nausea—Irbesartan—type 2 diabetes mellitus	2.3e-05	0.000183	CcSEcCtD
Sibutramine—Rash—Losartan—type 2 diabetes mellitus	2.29e-05	0.000183	CcSEcCtD
Sibutramine—Dermatitis—Losartan—type 2 diabetes mellitus	2.29e-05	0.000183	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC9A1—type 2 diabetes mellitus	2.28e-05	0.00103	CbGpPWpGaD
Sibutramine—Headache—Losartan—type 2 diabetes mellitus	2.28e-05	0.000182	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—TRPC6—type 2 diabetes mellitus	2.27e-05	0.00102	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—CETP—type 2 diabetes mellitus	2.25e-05	0.00102	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—PLAT—type 2 diabetes mellitus	2.24e-05	0.00101	CbGpPWpGaD
Sibutramine—Asthenia—Ramipril—type 2 diabetes mellitus	2.24e-05	0.000178	CcSEcCtD
Sibutramine—SLC6A3—Neuronal System—CALM1—type 2 diabetes mellitus	2.23e-05	0.00101	CbGpPWpGaD
Sibutramine—Pruritus—Ramipril—type 2 diabetes mellitus	2.21e-05	0.000176	CcSEcCtD
Sibutramine—Nausea—Losartan—type 2 diabetes mellitus	2.16e-05	0.000172	CcSEcCtD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—TNF—type 2 diabetes mellitus	2.15e-05	0.00097	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—type 2 diabetes mellitus	2.14e-05	0.000966	CbGpPWpGaD
Sibutramine—Diarrhoea—Ramipril—type 2 diabetes mellitus	2.13e-05	0.00017	CcSEcCtD
Sibutramine—SLC6A3—Neuronal System—PRKCB—type 2 diabetes mellitus	2.1e-05	0.000946	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—TGFB1—type 2 diabetes mellitus	2.09e-05	0.000942	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—ALB—type 2 diabetes mellitus	2.08e-05	0.000938	CbGpPWpGaD
Sibutramine—Dizziness—Ramipril—type 2 diabetes mellitus	2.06e-05	0.000164	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC2A4—type 2 diabetes mellitus	2.05e-05	0.000926	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—MTR—type 2 diabetes mellitus	2.01e-05	0.000908	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—PLAT—type 2 diabetes mellitus	1.99e-05	0.000897	CbGpPWpGaD
Sibutramine—Vomiting—Ramipril—type 2 diabetes mellitus	1.98e-05	0.000158	CcSEcCtD
Sibutramine—Rash—Ramipril—type 2 diabetes mellitus	1.97e-05	0.000157	CcSEcCtD
Sibutramine—Dermatitis—Ramipril—type 2 diabetes mellitus	1.97e-05	0.000157	CcSEcCtD
Sibutramine—Headache—Ramipril—type 2 diabetes mellitus	1.95e-05	0.000156	CcSEcCtD
Sibutramine—CYP3A4—Biological oxidations—CYP11A1—type 2 diabetes mellitus	1.95e-05	0.000879	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—CYP11A1—type 2 diabetes mellitus	1.92e-05	0.000867	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—type 2 diabetes mellitus	1.89e-05	0.000855	CbGpPWpGaD
Sibutramine—Nausea—Ramipril—type 2 diabetes mellitus	1.85e-05	0.000148	CcSEcCtD
Sibutramine—SLC6A3—NRF2 pathway—TGFB1—type 2 diabetes mellitus	1.85e-05	0.000834	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—ALB—type 2 diabetes mellitus	1.84e-05	0.000831	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC2A4—type 2 diabetes mellitus	1.82e-05	0.00082	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—GNB3—type 2 diabetes mellitus	1.77e-05	0.000798	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—HMOX1—type 2 diabetes mellitus	1.76e-05	0.000794	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—AVP—type 2 diabetes mellitus	1.74e-05	0.000787	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—IL6—type 2 diabetes mellitus	1.73e-05	0.000783	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—APOB—type 2 diabetes mellitus	1.69e-05	0.000761	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—CYP2E1—type 2 diabetes mellitus	1.61e-05	0.000726	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—CYP1A2—type 2 diabetes mellitus	1.59e-05	0.000717	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—CYP2E1—type 2 diabetes mellitus	1.59e-05	0.000716	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	1.58e-05	0.000711	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—CYP1A2—type 2 diabetes mellitus	1.57e-05	0.000708	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—GNB3—type 2 diabetes mellitus	1.57e-05	0.000707	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—HMOX1—type 2 diabetes mellitus	1.56e-05	0.000704	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—AVP—type 2 diabetes mellitus	1.54e-05	0.000697	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—APOB—type 2 diabetes mellitus	1.49e-05	0.000674	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	1.42e-05	0.000642	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—IL6—type 2 diabetes mellitus	1.42e-05	0.000639	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	1.4e-05	0.00063	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	1.33e-05	0.000602	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	1.26e-05	0.000568	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—GSTM1—type 2 diabetes mellitus	1.22e-05	0.00055	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—GSTM1—type 2 diabetes mellitus	1.2e-05	0.000542	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	1.18e-05	0.000533	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	1.06e-05	0.000477	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	9.36e-06	0.000422	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—BHMT—type 2 diabetes mellitus	9.29e-06	0.000419	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—AANAT—type 2 diabetes mellitus	8.12e-06	0.000367	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PTGDS—type 2 diabetes mellitus	8.12e-06	0.000367	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GPD2—type 2 diabetes mellitus	7.7e-06	0.000348	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CDO1—type 2 diabetes mellitus	7.7e-06	0.000348	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—AK1—type 2 diabetes mellitus	7.34e-06	0.000332	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SLC5A4—type 2 diabetes mellitus	6.78e-06	0.000306	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—MAT1A—type 2 diabetes mellitus	6.78e-06	0.000306	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PPP1R3C—type 2 diabetes mellitus	6.55e-06	0.000295	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ENPP1—type 2 diabetes mellitus	6.55e-06	0.000295	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ND1—type 2 diabetes mellitus	6.55e-06	0.000295	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—G6PC—type 2 diabetes mellitus	6.55e-06	0.000295	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—HBA2—type 2 diabetes mellitus	6.55e-06	0.000295	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GCGR—type 2 diabetes mellitus	6.34e-06	0.000286	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	5.99e-06	0.00027	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	5.99e-06	0.00027	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	5.83e-06	0.000263	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	5.57e-06	0.000251	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	5.57e-06	0.000251	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	5.57e-06	0.000251	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	5.34e-06	0.000241	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	5.34e-06	0.000241	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	5.14e-06	0.000232	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	5.14e-06	0.000232	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	5.05e-06	0.000228	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	4.96e-06	0.000224	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	4.96e-06	0.000224	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	4.96e-06	0.000224	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	4.66e-06	0.000211	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	4.37e-06	0.000197	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	4.22e-06	0.00019	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	4.22e-06	0.00019	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	4.22e-06	0.00019	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	4.22e-06	0.00019	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	4.04e-06	0.000183	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	3.76e-06	0.00017	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	3.51e-06	0.000158	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	3.44e-06	0.000155	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	3.44e-06	0.000155	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	3.37e-06	0.000152	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	3.35e-06	0.000151	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	3.35e-06	0.000151	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	3.35e-06	0.000151	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	3.33e-06	0.00015	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	3.27e-06	0.000148	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	3.23e-06	0.000146	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	3.01e-06	0.000136	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	3.01e-06	0.000136	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	3.01e-06	0.000136	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	2.95e-06	0.000133	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	2.92e-06	0.000132	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	2.86e-06	0.000129	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	2.75e-06	0.000124	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	2.72e-06	0.000123	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	2.72e-06	0.000123	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	2.61e-06	0.000118	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	2.61e-06	0.000118	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	2.25e-06	0.000101	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.25e-06	0.000101	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	2.24e-06	0.000101	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	2.21e-06	9.96e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	2.14e-06	9.67e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	2.08e-06	9.4e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	2.04e-06	9.23e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	2e-06	9.04e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	1.99e-06	9.01e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	1.94e-06	8.77e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	1.92e-06	8.66e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	1.84e-06	8.31e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	1.81e-06	8.15e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	1.75e-06	7.9e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	1.72e-06	7.76e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	1.71e-06	7.74e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	1.69e-06	7.65e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	1.49e-06	6.74e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	1.46e-06	6.61e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	1.34e-06	6.06e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	1.28e-06	5.8e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	1.28e-06	5.8e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	1.17e-06	5.3e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	5.9e-07	2.66e-05	CbGpPWpGaD
